Joseph Risser
Family Medicine · San Diego, CANPI 1952386765
Payments from drug & device makers
Across 2,083 payments — averaging $308.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$627K
- Abbott$13K
- Novo Nordisk$2K
- Amgen$152
- Corcept Therapeutics$75
- AstraZeneca$75
- plus $175 from 6 others
Across 6 payments — averaging $388.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Consulting fees$9458%
- Travel & lodging$8,18773%
- Food & beverage$2,00718%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 1,955 | $627,018 |
| Abbott | 15 | $12,695 |
| Novo Nordisk | 95 | $2,264 |
| Amgen | 2 | $152 |
| Corcept Therapeutics | 4 | $75 |
| AstraZeneca | 3 | $75 |
| Hologic Sales And Service, LLC | 3 | $70 |
| Dexcom, Inc. | 2 | $43 |
| Valeritas, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$642,454 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 59 | $97,665 |
| JardianceEmpagliflozin | 75 | $89,262 |
| OzempicSemaglutide | 57 | $60,831 |
| TrulicityDulaglutide | 36 | $52,260 |
| Atrovent HfaIpratropium Bromide | 90 | $50,197 |
| EliquisApixaban | 56 | $46,217 |
| JanuviaSitagliptin Phosphate | 37 | $42,924 |
| FarxigaDapagliflozin Propanediol | 30 | $37,265 |
| XareltoRivaroxaban | 15 | $20,892 |
| EntrestoSacubitril/Valsartan | 12 | $16,321 |
| VascepaIcosapent Ethyl | 13 | $9,385 |
| DuleraMometasone/Formoterol | 14 | $6,286 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $5,305 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,034 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 126 | $4,883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $2,264 | $158,496116 claims |
| AstraZenecaFarxiga | $75 | $37,26530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in San Diego
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Laurie Han-ConradSan Diego$2.9M
- Sheldon MorrisSan Diego$1.1M
- Mirwais SaifiSan Diego$1M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.